Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation

Antibody mediated rejection (AMR) after adult ABO-incompatible living donor liver transplantation (ABO-I LDLT) induced hepatic necrosis or diffuse intrahepatic biliary complications, which were related with poor graft and patient survival. Various desensitization protocols have been used to overcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Jongwook, Kim, Jong Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940481/
https://www.ncbi.nlm.nih.gov/pubmed/30909688
http://dx.doi.org/10.3350/cmh.2019.0023
_version_ 1783484353409449984
author Oh, Jongwook
Kim, Jong Man
author_facet Oh, Jongwook
Kim, Jong Man
author_sort Oh, Jongwook
collection PubMed
description Antibody mediated rejection (AMR) after adult ABO-incompatible living donor liver transplantation (ABO-I LDLT) induced hepatic necrosis or diffuse intrahepatic biliary complications, which were related with poor graft and patient survival. Various desensitization protocols have been used to overcome these problems. Since using rituximab, the outcomes of ABO-I LDLT show a similar survival rate to those of ABO-compatible living donor liver transplantation. However, diffuse bile duct complications still occur after ABO-I LDLT. We have reviewed the past and current immune strategies for desensitization and to provide outcomes and ABO incompatibility-related complications in ABO-I LDLT.
format Online
Article
Text
id pubmed-6940481
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Association for the Study of the Liver
record_format MEDLINE/PubMed
spelling pubmed-69404812020-01-06 Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation Oh, Jongwook Kim, Jong Man Clin Mol Hepatol Review Antibody mediated rejection (AMR) after adult ABO-incompatible living donor liver transplantation (ABO-I LDLT) induced hepatic necrosis or diffuse intrahepatic biliary complications, which were related with poor graft and patient survival. Various desensitization protocols have been used to overcome these problems. Since using rituximab, the outcomes of ABO-I LDLT show a similar survival rate to those of ABO-compatible living donor liver transplantation. However, diffuse bile duct complications still occur after ABO-I LDLT. We have reviewed the past and current immune strategies for desensitization and to provide outcomes and ABO incompatibility-related complications in ABO-I LDLT. The Korean Association for the Study of the Liver 2020-01 2019-03-26 /pmc/articles/PMC6940481/ /pubmed/30909688 http://dx.doi.org/10.3350/cmh.2019.0023 Text en Copyright © 2020 by The Korean Association for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Oh, Jongwook
Kim, Jong Man
Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation
title Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation
title_full Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation
title_fullStr Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation
title_full_unstemmed Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation
title_short Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation
title_sort immunologic strategies and outcomes in abo-incompatible living donor liver transplantation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940481/
https://www.ncbi.nlm.nih.gov/pubmed/30909688
http://dx.doi.org/10.3350/cmh.2019.0023
work_keys_str_mv AT ohjongwook immunologicstrategiesandoutcomesinaboincompatiblelivingdonorlivertransplantation
AT kimjongman immunologicstrategiesandoutcomesinaboincompatiblelivingdonorlivertransplantation

Ejemplares similares